PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
Tag: Pulmonary Hypertension
Recent
egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Popular
- No commented posts yet